[HTML][HTML] Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/-mice
Since atherosclerosis is a chronic inflammatory disease, we tested the hypothesis that the
immunosuppressive drug FK506 would attenuate the development of atherosclerosis using
a mouse model of collar-induced atherosclerosis. ApoE-/-mice were treated for 4 weeks with
the immunosuppressive drug FK506 (0.05 mg/kg/day), yielding sustained blood levels (~ 0.2
ng/mL) without systemic side effects. Atherosclerotic plaque development of FK506-treated
mice was significantly reduced (63%) while plaque cell density was increased (52%) …
immunosuppressive drug FK506 would attenuate the development of atherosclerosis using
a mouse model of collar-induced atherosclerosis. ApoE-/-mice were treated for 4 weeks with
the immunosuppressive drug FK506 (0.05 mg/kg/day), yielding sustained blood levels (~ 0.2
ng/mL) without systemic side effects. Atherosclerotic plaque development of FK506-treated
mice was significantly reduced (63%) while plaque cell density was increased (52%) …
